Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp

Year in Review: Dr. P Seo ⭐️Does Pizza consumption favor improved dz activity in RA? If in Italy ➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz ➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6) ➡️Mozzarella & olive oil showed beneficial effects #ACR23 @RheumNow https://t.co/qZTzThI39e

YR in Review: Dr. P Seo ⭐️Sarilumab for relapse of PMR during GC taper: ➡️ab against IL6R ➡️118 pts: ⏺️pred 15 mg/d ⏺️Sari 200 mg/d q2wk/14wk ⏺️52wk pred taper ➡️At wk 52: ⏺️sustained remission: 28% vs 10% ⏺️mean total GC: 777 vs 2044 mg #ACR23 @RheumNow https://t.co/ETVpyuBlZ7

Towards more personalised care in rheumatoid arthritis #ACR23 @RheumNow https://t.co/roxtcX8QHI

There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz

RA as a young woman used to mean kids were only a distant thought. Japanese RA pts n=280 asked whether RA onset meant wanting fewer children & why. Confidence improving across the board over time. We want to give our RA pts choices to live their life! #ACR23 ABST0473 @RheumNow https://t.co/OHZM2J5qxS

Tired of getting referrals for symptomatic patients with 1/80+ ANAs antibodies? This new risk model for systemic AID is very welcome! Variables: age, female, higher ANA titer, higher platelet count, disease-specific autoantibody & billing code count. #ACR23 @Rheumnow ABST0131 https://t.co/q8rYjjtZ89

Year in Review: Dr. P Seo Dr. Seo gave a moment of silence to Baricitinib use in SLE given studies showing it is not efficacious for SLE #ACR23 @RheumNow https://t.co/8GKUlfJdbe

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE COMPLETE ➡️ TNFi failures ➡️Phase III, 400 pts, bimekizumab, PBO ➡️ Wk 16: improvements in joint and skin #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE OPTIMAL ➡️ tx-naive ➡️Phase III, 852 pts, bimekizumab, PBO, ADA ➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & type I IFN ➡️ Phase Ib, 218 pts, 8% TNFi failure ➡️ 71% on concurrent MTX ➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52 #ACR23 @RheumNow

These US Medicare data show us what we've all suspected: PMR patients stuck on steroid get the fractures, heart attacks, & infections that land them in hospital. And it costs $$$ Hopefully PMR steroid-sparing Rx can change this! @RADoctor @SattuiSEMD #ACR23 ABST0718 @RheumNow https://t.co/XAWmf2qZAU

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️ABBV-3373 ➡️ Adalimumab (ADA) + GC receptor modulator vs ADA ➡️ Phase II, 48 pts, previously failed MTX ➡️ Wk 12: better DAS28-CRP, ACR20/70 🚩71% of responders stayed in remission after switch to PBO #ACR23 @RheumNow

Difficult to treat RA is not an homogeneous group! Trajectory analysis 60months shows 4 different clusters Cluster 2 = 1/3 of patients, do better but never reach LDA. The ones Fibromyalgia, OA and other conditions blurring assessment? #Abstract0382 #ACR23 @RheumNow https://t.co/dxxS7vCcMt

Dr. Arbeeva explains how a "modern diet" can lead to MetS, intestinal dysbiosis & obesity - risk factors assoc w/ development of #osteoarthritis Modern diet: ⬆️calorie processed food ⬇️proportion of fruits & veggies ⬆️ratio of omega-6 FA:omega-3FA #ACR23 @rheumnow @rheumarhyme https://t.co/biVSE103S0